

PERSONAL INFORMATION

Nectaroula Cooper

WORK EXPERIENCE

March 2018–Present

Pharmacist

Pharmaceutical Services, Ministry of Health (Cyprus)

- Administration
- Regulatory Affairs
- GMDP Inspectorate

Cyprus Member of the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency

Member of the national sub-committee of the Drugs Council for Pharmacovigilance

Member of the national sub-committee of the Drugs Council for Clinical Trials

Member of the national sub-committee of the Drugs Council for the legal classification of medicines

January 2017–March 2018

Pharmacist

Nicosia General Hospital Pharmacy, Pharmaceutical Services, Ministry of Health (Cyprus)

December 2013–December 2016

Head of Pharmacovigilance

Pharmaceutical Services, Ministry of Health (Cyprus)

EU contact point for Pharmacovigilance matters

PRAC (Pharmacovigilance Risk Assessment Committee) Member for Cyprus

Member of the national sub-committee on Pharmacovigilance

Member of the Strategic Planning Task Force

Product Shortages and development of policies concerning Medicines Accessibility

April 2011–December 2013

Pharmacist

Pharmaceutical Services, Ministry of Health (Cyprus)

Hospital pharmacist based at Nicosia General Hospital (from July 2011) with secondments to Limassol Outpatient Hospital (inc. rural pharmacy services in Limassol district). Pharmacist at Larnaca General Hospital (April 2011) and Responsible Pharmacist at Pyrgo Tyllirias Rural Health Centre (May - July 2011).

Member of the committee for infectious diseases at NGH.

April 2010–April 2011

Locum Pharmacist

Pavidou & Michael Pharmacy (Cyprus)

Part time locum Pharmacist

May 2007–March 2010

Global QPPV and Regulatory Affairs officer

Medochemie Ltd. (Cyprus)

Global and EU Qualified Person for Pharmacovigilance (EU-QPPV)

Product Quality Expert

RA country manager for Malta

API manufacturers qualification

April 2004–April 2007

Locum Pharmacist

Community Pharmacies, Limassol (Cyprus)
Part time locum pharmacist.

October 2000–September 2003

Locum Pharmacist

Community Pharmacies, London & Nottingham (Cyprus)
Weekend Locum Pharmacist

February 2000–September 2000

Pre-registration Pharmacist

St George's Hospital, London (United Kingdom)
Approved pre-registration practical training in hospital pharmacy.

August 1999–January 2000

Pre-registration Pharmacist

Abbott Labs, Queenborough, Kent (United Kingdom)
Approved pre-registration practical training in industrial pharmacy.

July 1998–September 1998

Internship

Remedica Pharmaceuticals Ltd., Limassol (Cyprus)
Work experience in pharmaceutical Research and Development.

April 1998–May 1998

Internship

Smith and Nephew Medical Ltd., Hull (United Kingdom)
Work experience in International Marketing.

EDUCATION AND TRAINING– **PhD**

School of Pharmacy, University of London (United Kingdom)

Dissertation title: "**Design, synthesis and evaluation of novel C2-aryl pyrrolobenzodiazepines as potential anticancer agents**"

Academic Advisers: Prof. David E. Thurston, Dr Phil W. Howard

CRUK Gene Targeted Drug Design Research Group, Pharmaceutical & Biological Chemistry Department;

Cancer Research UK Scholarship

– **Master in Business Administration (MBA)**

University of Cyprus (Cyprus)

Thesis title: "**Proposals for new business models towards smart grid application in Cyprus**"

Academic advisor: Prof. Andreas Soteriou

School of Economics and Management

– **MRPharmS**

Member of the Royal Pharmaceutical Society (United Kingdom)

RPSGB Pre-registration split industry/hospital training program.

– **BSc (Hons.) Pharmacy**

University of Sunderland (United Kingdom)

Dissertation and elective in medicinal chemistry.

– **Diploma in EU Public Procurement**

ALISON (Ireland)

Modules included: Introduction to EU public procurement; EU Public Procurement - Development Specifications; Procedures; Writing the RFT Document; Implementation; Ethics; Assessment.

ADDITIONAL INFORMATION

Expertise

- Drug Discovery and Development, Design and Synthesis
- Medicines Accessibility and Reimbursement of Medicines
- Medicinal Cannabis
- Pharmacovigilance and drug safety
- Regulatory Affairs
- Pharmacy Practice & Policy
- Biosimilars

- Publications**
- Antonow, D.; Kaliszczak, M.; Kang, G. D.; Coffils, M.; Tiberghien, A. C.; Cooper, N.; Barata, T.; Heidelberger, S.; James, C. H.; Zloh, M.; Jenkins, T. C.; Reszka, A. P.; Neidle, S.; Guichard, S. M.; Jodrell, D. I.; Hartley, J. A.; Howard, P. W.; Thurston, D. E., Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor agents. *J Med Chem* 2010, 53 (7), 2927-41.
 - Howard, P. W.; Chen, Z.; Gregson, S. J.; Masterson, L. A.; Tiberghien, A. C.; Cooper, N.; Fang, M.; Coffils, M. J.; Klee, S.; Hartley, J. A.; Thurston, D. E., Synthesis of a novel C2/C2'-arylsubstituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate. *Bioorg Med Chem Lett* 2009, 19 (22), 6463-6.
 - Antonow, D.; Cooper, N.; Howard, P. W.; Thurston, D. E., Parallel synthesis of a novel C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) library. *J Comb Chem* 2007, 9 (3), 437-45.
 - Cooper, N.; Hagan, D. R.; Tiberghien, A.; Ademefun, T.; Matthews, C. S.; Howard, P. W.; Thurston, D. E., Synthesis of novel C2-aryl pyrrolobenzodiazepines (PBDs) as potential antitumour agents. *Chem Commun (Camb)* 2002, (16), 1764-5.
 - Cooper N, Hagan DR, Tiberghien A, Ademefun T, Matthews CS, Howard PW, et al. Synthesis of novel C2-aryl pyrrolobenzodiazepines (PBDs) as potential antitumour agents. *Chemical Biology Virtual Journal* [serial online]. 2002;(14) [cited 2006 November 1]. Available from: URL: www.rsc.org/Publishing/Journals/cb/Index.asp.

Conference proceedings:

- Polypharmacy – Patient Safety and Quality of Life. Polythematic scientific conference 2012; 8 December 2012; Nicosia General Hospital.
- Howard PW, Antonow D, Cooper N, Stephenson M, Hartley JA, Jenkins TC, et al. Design, synthesis and biological evaluation of novel C2-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine monomers. In: 97th AACR Annual Meeting; AACR Meeting Abstracts; 2006 April 1-5; Washington, DC. Philadelphia: Proc Amer Assoc Cancer Res (American Association for Cancer Research, Inc. (AACR)); 2006;47(1): p. 132-a-.
- Cooper N, Howard PW, Neidle S, Thurston DE. Synthesis and evaluation of novel C2-aryl pyrrolobenzodiazepine (PBD) monomers as potential clinical candidates. In: Mini E, Mazzei T, Novelli A, Nobili S, Forrest M, Landini I, et al., editors. 24th Winter Meeting of the EORTC PAMM Group; *Journal of Chemotherapy Supplement (Abstracts)*; 2003 February 5-8; Convitto della Calza, Florence, Italy. Firenze: J. Chemother. (University of Florence); 2003;15(Supplement 1): p. 129 (P22).
- Cooper N, Burger AM, Fiebig HH, Howard PW, Neidle S, Thurston DE. Structure-Activity-Relationship (SAR) study of novel C2/C3-unsaturated C2-aryl-substituted pyrrolobenzodiazepine monomer antitumour agents. In: Smyth JF, editor. 14th EORTC-NCIAACR symposium on Molecular Targets and Cancer Therapeutics; *European Journal of Cancer*; 2002 November 19-22

Frankfurt am Main, Germany. Oxford: Eur. J. Cancer (Pergamon/Elsevier); 2002;38(Supplement 7): p. S122.

- Cooper N, Hagan DR, Ademefun T, Tiberghien A, Matthews CS, Burger AM, et al. Synthetic C2-aryl pyrrolobenzodiazepines as potential melanoma chemotherapy agents. In: Lejeune FJ, Riley PA, Storkus WJ, editors. 4th International Conference on the Adjuvant Therapy of Malignant Melanoma; 2002 March 15-16; Royal College of Physicians, London, UK. London: Melanoma Res. (Lippincott Williams & Wilkins); 2002;12(3): p. A24-A40.
- Cooper N, Hagan DR, Ademefun T, Tiberghien A, Gregson SJ, Howard PW, et al. Design, synthesis and evaluation of novel anti-melanoma agents. In: York P, editor. 138th British Pharmaceutical Conference; Science Proceedings 2001; 2001 September 23-26; Glasgow, Scotland. London: J. Pharm. Pharmacol. (Pharmaceutical Press); 2001; p. 243.
- Cooper N, Howard PW, Neidle S, Thurston DE. Synthesis and evaluation of novel C2-aryl pyrrolobenzodiazepine (PBD) monomers as potential clinical candidates. In: CRUK Students Meeting 2003; 2003 19 May 2003; London, UK.
- Cooper N, Burger AM, Matthews CS, Howard PW, Thurston DE. Synthetic C2-aryl pyrrolobenzodiazepines as potential melanoma chemotherapy agents. In: Zloh M, chair. School of Pharmacy Postgraduate Research Day; 2002 April 17; School of Pharmacy, University of London, London, UK.
- Cooper N. Audit on the Frequency of Blood-Glucose Testing in St. George's Hospital In-Patients. In: Pharmacy Pre-Registration Meeting - South Thames Region; 2000 July 13; Guys & Thomas' Hospital, London, UK

Projects

- "Accessibility and Affordability of Innovative Medicines throughout the EU Market", Pharmaceutical Services, Ministry of Health, Cyprus, 2018 (ongoing)
- "Legalisation of Medicinal Cannabis for Medical Use", Ministry of Health, Cyprus, 2016 - 2018 (ongoing)
- "Establishment of a National Medicines Agency in Cyprus", Ministry of Health, Cyprus, 2016 - 2018 (ongoing)
- "Polypharmacy - detailed analysis of the problem in public health care", Pharmaceutical Services, Ministry of Health, Cyprus, 2018
- "New Innovative Medicines Procurement in the Context of Small Markets", Pharmaceutical Services, Ministry of Health, Cyprus, 2015
- "Pharmaceutical Services, State of Play, Objectives and Activities (ABB)", Ministry of Health, Cyprus, 2015
- "Working Group for the Management of Cancer Medication" Cyprus Ministry of Health.
- "Polypharmacy - patient safety and quality of life", Nicosia General Hospital, 2012
- "Hazardous drugs in the hospital setting", Nicosia General Hospital, 2012
- "Audit on the frequency of blood glucose testing in St George's Hospital in-patients", London, 2000
- "Synthesis of anthraquinone-amino acid conjugates as potential topoisomerase inhibitors in the treatment of cancer", Sunderland, 1999

Memberships

- Registered Pharmacist with the General Pharmaceutical Council, Great Britain
- Member of the Royal Pharmaceutical Society, GB
- Registered Pharmacist of the Republic of Cyprus
- Member of the Academy of Pharmaceutical Sciences, UK

Committees

- Member of the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) (Representing Cyprus)
- Member of the Clinical Trials Committee of the Drugs Council (Cyprus)
- Member of the Pharmacovigilance Committee of the Drugs Council (Cyprus)
- Member of the Legal Classification of Medicines Committee of the Drugs Council (Cyprus)

Formerly:

- PRAC (Pharmacovigilance Risk Assessment Committee at the European Medicines Agency) Member for Cyprus
- Pharmacovigilance Business Team (EMA) Member
- EU Network Training Center Learning Management System Local Administrator
- Member of the Infectious Diseases committee, Nicosia General Hospital, Cyprus
- Member of Task Force for the development and implementation of guidelines on the safe handling of hazardous drugs, Nicosia General Hospital
- Lead of 'Working Group for the Management of Cancer Medication', Ministry of Health, Cyprus

Other Relevant InformationAwards

The Schering-Plough Young Investigator Award, '4th International Conference on the Adjuvant Therapy of Malignant Melanoma', Royal College of Physicians, London March 2002.